TL;DR: Beyond Tirzepatide, three receptor-expanding compounds define 2026’s research pipeline — Retatrutide (GLP-1 + GIP + glucagon triple agonist, ~24% weight loss in trials), CagriSema (GLP-1 + amylin, ~23%), and Survodutide (GLP-1/glucagon, liver-focused). Orforglipron adds an oral small-molecule option. Retatrutide remains the most research-available compound of the group.
The GLP-1 revolution started with Semaglutide, accelerated with Tirzepatide, and in 2026, the next generation is arriving. These new compounds promise even greater efficacy through multi-receptor mechanisms and novel delivery methods. Here’s what researchers need to know.
The Evolution of Incretin-Based Peptides
The Progression
| Generation | Example | Mechanism | Avg Weight Loss |
|---|---|---|---|
| 1st | Semaglutide | GLP-1 | ~15-17% |
| 2nd | Tirzepatide | GLP-1 + GIP | ~20-22% |
| 3rd | Retatrutide | GLP-1 + GIP + Glucagon | ~24%+ |
Each generation adds receptor targets for enhanced metabolic effects. For a deeper side-by-side look at how these three peptides compare on dosing and outcomes, see our Semaglutide vs. Tirzepatide vs. Retatrutide comparison.
Retatrutide: The Triple Agonist
Retatrutide is Eli Lilly’s triple receptor agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. For background on the compound itself, see What Is Retatrutide?
Mechanism of Action
| Receptor | Effect |
|---|---|
| GLP-1 | Appetite suppression, glucose control |
| GIP | Insulin sensitivity, fat metabolism |
| Glucagon | Energy expenditure, liver fat reduction |
The glucagon component is the key differentiator — it increases energy expenditure and specifically targets liver fat.
Clinical Data
Phase 2 trials showed remarkable results:
| Dose (weekly) | 48-Week Weight Loss |
|---|---|
| 4mg | ~17% |
| 8mg | ~22% |
| 12mg | ~24.2% |
The 12mg dose achieved greater average weight loss than any previously reported obesity medication.
Current Status
- Phase 3 trials ongoing
- Expected FDA submission: 2026
- Potential approval: Late 2026 or 2027
Research Availability
Retatrutide is available from research peptide suppliers:
| Vial Size | Common Use |
|---|---|
| 5mg | Starting/titration protocols |
| 10mg | Established protocols |
Reconstitution Quick Reference
| Vial | BAC Water | Concentration | 4mg Dose |
|---|---|---|---|
| 5mg | 1mL | 5mg/mL | 0.8mL (80 units) |
| 10mg | 2mL | 5mg/mL | 0.8mL (80 units) |
At 5mg/mL, a 4mg draw = 0.8 mL = 80 units on a U-100 syringe.
CagriSema: The Amylin Combo
CagriSema is Novo Nordisk’s answer to the next generation — a fixed-dose combination of cagrilintide (amylin analog) and semaglutide. See What Is CagriSema? for a closer look at the combination.
Why Amylin?
Amylin is a hormone co-secreted with insulin that:
- Slows gastric emptying
- Promotes satiety
- Reduces glucagon secretion
Combining it with GLP-1 hits two complementary satiety pathways.
The Components
| Component | Class | Role |
|---|---|---|
| Cagrilintide | Amylin analog | Satiety enhancement |
| Semaglutide | GLP-1 agonist | Appetite/glucose control |
Clinical Results
Phase 3 REDEFINE trials showed:
| Metric | CagriSema | Semaglutide 2.4mg |
|---|---|---|
| Weight loss (68 weeks) | ~22.7% | ~15.8% |
| Patients losing 20%+ | ~55% | ~30% |
CagriSema significantly outperformed semaglutide alone.
Timeline
- FDA submission expected: 2026
- Potential approval: 2026-2027
Research Note
Cagrilintide is not yet widely available as a standalone research peptide. Researchers interested in amylin pathways may explore pramlintide (the approved amylin analog for diabetes) or the 5mg cagrilintide vials now offered by some research suppliers.
Orforglipron: The Oral GLP-1
Orforglipron represents a different kind of breakthrough — it’s an oral small-molecule GLP-1 agonist, not a peptide.
Why This Matters
Current GLP-1s are peptides requiring injection because:
- Peptides are degraded by stomach acid
- Poor oral bioavailability
- Must be injected subcutaneously
Orforglipron is a small molecule that mimics GLP-1 effects orally.
Advantages
| Factor | Injectable GLP-1 | Orforglipron |
|---|---|---|
| Delivery | Subcutaneous injection | Daily pill |
| Cold storage | Required | Not required |
| Needle aversion | Barrier for some | Eliminated |
| Travel | Requires supplies | Simple |
Clinical Data
Eli Lilly Phase 3 data:
- Significant weight loss comparable to injectable GLP-1s
- Once-daily oral dosing
- Generally well-tolerated
Timeline
- FDA approval expected: March 2026 (per Reuters report)
- Could become first truly convenient oral option
Implications for Research
If orforglipron succeeds, it suggests:
- Small-molecule GLP-1 mimetics are viable
- Future weight loss treatments may be oral-first
- Injectable peptides may become “second-line” for some
Survodutide: The Boehringer Entry
Survodutide is Boehringer Ingelheim’s dual GLP-1/glucagon receptor agonist. See our Survodutide vs. Mazdutide comparison for how it stacks up against another dual agonist in research circulation.
Mechanism
Similar to Retatrutide but without GIP:
- GLP-1 receptor agonism (appetite)
- Glucagon receptor agonism (energy expenditure, liver fat)
Why It’s Interesting
The glucagon component specifically targets:
- Non-alcoholic fatty liver disease (NAFLD)
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Visceral fat reduction
Phase 2 data showed significant liver fat reduction alongside weight loss.
Current Status
- Phase 3 trials for obesity and MASH ongoing
- Potential 2026-2027 submissions
Pemvidutide: The Dual Without GIP
Alto Neuroscience is developing pemvidutide, another GLP-1/glucagon dual agonist.
Differentiator
Designed for once-weekly dosing with emphasis on:
- MASH/liver disease
- Obesity with liver involvement
- Metabolic health beyond weight
Phase 2 results showed ~15% weight loss with significant liver fat reduction.
Comparison: The Next-Gen Landscape
| Compound | Mechanism | Weight Loss | Key Advantage |
|---|---|---|---|
| Retatrutide | GLP-1/GIP/Glucagon | ~24% | Highest efficacy |
| CagriSema | GLP-1 + Amylin | ~23% | Dual satiety pathways |
| Orforglipron | GLP-1 (oral) | ~15%+ | No injection needed |
| Survodutide | GLP-1/Glucagon | ~19% | Liver-focused |
| Pemvidutide | GLP-1/Glucagon | ~15% | MASH indication |
Approximate average weight loss reported across each compound's trials.
What This Means for Researchers
The Current Opportunity
While pharmaceutical versions are in trials, research-grade peptides are available:
| Peptide | Research Status |
|---|---|
| Retatrutide | Available from research suppliers |
| Tirzepatide | Widely available |
| Semaglutide | Widely available |
| Cagrilintide | Limited availability |
Protocol Considerations
For researchers exploring triple agonism:
Retatrutide Titration Protocol (Example)
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 1mg weekly | Initial titration |
| 5-8 | 2mg weekly | Assess tolerance |
| 9-12 | 4mg weekly | Standard dose |
| 13+ | 4-8mg weekly | Based on protocol needs |
- 1
Weeks 1-4
1mg weekly — initial titration.
- 2
Weeks 5-8
2mg weekly — assess tolerance.
- 3
Weeks 9-12
4mg weekly — standard dose.
- 4
Week 13+
4-8mg weekly — based on protocol needs.
Key Differences from GLP-1-only:
- More pronounced appetite suppression
- Greater GI side effects initially
- More significant energy expenditure increase
- Requires slower titration
Side Effect Profile
Triple agonists may have increased:
- Nausea and vomiting (especially early)
- Heart rate elevation
- GI discomfort
- Initial adaptation period
The glucagon component adds metabolic activation that some find noticeable.
The Bigger Picture: 2026 and Beyond
Market Evolution
| Timeline | Development |
|---|---|
| 2024-2025 | Tirzepatide dominance |
| 2026 | Orforglipron approval, Retatrutide late-stage |
| 2027 | Multiple next-gen options available |
| 2028+ | Oral options may dominate |
Research Implications
- Triple agonism represents the efficacy frontier for injectables
- Oral delivery may transform accessibility
- Combination approaches (GLP-1 + amylin, etc.) show synergy
- Liver-focused compounds address MASH epidemic
For Current Researchers
The best time to understand these compounds is before they’re mainstream:
- Retatrutide is available now for research
- Tirzepatide protocols inform triple-agonist approaches
- Understanding mechanism differences aids protocol design
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials. Our Peptide Quality & Safety Guide covers how to read a COA and vet a supplier in more depth.
FAQ
What is the difference between Retatrutide and Tirzepatide? Tirzepatide is a dual GLP-1/GIP agonist producing roughly 20-22% average weight loss in trials. Retatrutide adds a third glucagon-receptor target, pushing average trial weight loss above 24%. Researchers comparing the two should note the added energy-expenditure and liver-fat effects the glucagon component contributes relative to dual-agonist protocols.
Is Retatrutide available for research use in 2026? Yes — Retatrutide is currently one of the more accessible next-generation compounds through research peptide suppliers, sold in 5mg and 10mg vials for laboratory use. It remains in Phase 3 trials pharmaceutically, so any research application should rely on verified certificates of analysis rather than clinical-trial dosing assumptions.
What makes CagriSema different from Semaglutide alone? CagriSema pairs semaglutide with cagrilintide, an amylin analog, targeting two separate satiety pathways instead of one. Phase 3 REDEFINE data showed roughly 22.7% weight loss for CagriSema versus 15.8% for semaglutide alone, though cagrilintide itself remains more limited as a standalone research peptide.
Why does Orforglipron matter for peptide research if it isn’t a peptide? Orforglipron is a small-molecule oral GLP-1 agonist, not a peptide, yet its Phase 3 results rival injectable compounds. If it succeeds, it signals that oral small-molecule mimetics are viable, which could reshape how researchers weigh delivery-route trade-offs in future incretin-pathway study designs.
Do next-gen triple agonists need different titration than single-target GLP-1 peptides? Yes. Compounds like Retatrutide typically call for slower titration schedules than single-target GLP-1 peptides because the added glucagon activity increases early GI effects. Researchers commonly reference stepped titration protocols starting near 1mg weekly before reaching standard research doses.
Related Resources
- Semaglutide Dosage Guides
- Tirzepatide Dosage Guides
- Retatrutide Dosage Guides
- Switching from Semaglutide to Tirzepatide
- GLP-1 Microdosing Guide
Last updated: January 28, 2026
Disclaimer: This information is for educational and research purposes only. These peptides are research compounds not intended for human consumption. Pipeline drugs are subject to clinical trial outcomes and regulatory decisions.